Published in Clin Pharmacol Ther on October 31, 2007
Atomoxetine PBPK-PD Clinical Study | NCT03154359
Genetic Study of CYP2D6 Enzyme and Therapeutic Drug Monitoring of Tamoxifen | NCT03582865
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst (2012) 4.54
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther (2011) 3.09
Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others. Cleve Clin J Med (2011) 2.43
Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther (2013) 2.38
CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer (2009) 2.32
Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol (2010) 2.15
Length of psychiatric hospitalization is correlated with CYP2D6 functional status in inpatients with major depressive disorder. Biomark Med (2013) 2.13
A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin Pharmacol Ther (2012) 2.12
Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Genome Res (2010) 2.06
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther (2014) 1.84
Neonatal drug therapy: The first frontier of therapeutics for children. Clin Pharmacol Ther (2015) 1.60
Pharmacogenomic Research in South Africa: Lessons Learned and Future Opportunities in the Rainbow Nation. Curr Pharmacogenomics Person Med (2011) 1.49
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther (2015) 1.49
Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. Int J Mol Sci (2012) 1.44
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J (2009) 1.43
Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin (2009) 1.39
Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. Breast Cancer Res Treat (2009) 1.20
Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity. Hum Mol Genet (2013) 1.16
Antidepressant-induced akathisia-related homicides associated with diminishing mutations in metabolizing genes of the CYP450 family. Pharmgenomics Pers Med (2011) 1.10
Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects. Hum Genomics (2009) 1.06
Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate. Clin Pharmacol Ther (2014) 1.05
CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion. Clin Pharmacol Ther (2012) 1.02
Pharmacogenetics of antipsychotics. Can J Psychiatry (2014) 1.02
Identification of Novel CYP2D7-2D6 Hybrids: Non-Functional and Functional Variants. Front Pharmacol (2010) 1.01
In silico and in vitro identification of microRNAs that regulate hepatic nuclear factor 4α expression. Drug Metab Dispos (2012) 1.00
Frequency of undetected CYP2D6 hybrid genes in clinical samples: impact on phenotype prediction. Drug Metab Dispos (2011) 0.98
Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Res Treat (2011) 0.98
High-efficiency genotype analysis from formalin-fixed, paraffin-embedded tumor tissues. Pharmacogenomics J (2010) 0.98
The Coriell personalized medicine collaborative pharmacogenomics appraisal, evidence scoring and interpretation system. Genome Med (2013) 0.95
Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med (2016) 0.93
The CYP2D6 gene locus in South African Coloureds: unique allele distributions, novel alleles and gene arrangements. Eur J Clin Pharmacol (2008) 0.93
Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study. Genet Med (2008) 0.92
Variability in drug metabolizing enzyme activity in HIV-infected patients. Eur J Clin Pharmacol (2010) 0.91
CYP2D6 phenotype prediction from genotype: which system is the best? Clin Pharmacol Ther (2008) 0.91
Addressing phenoconversion: the Achilles' heel of personalized medicine. Br J Clin Pharmacol (2015) 0.90
PharmGKB summary: tramadol pathway. Pharmacogenet Genomics (2014) 0.89
The intersection of pharmacology, imaging, and genetics in the development of personalized medicine. Dialogues Clin Neurosci (2009) 0.89
Functional characterization of CYP2D6 enhancer polymorphisms. Hum Mol Genet (2014) 0.89
Evaluation of a [13C]-dextromethorphan breath test to assess CYP2D6 phenotype. J Clin Pharmacol (2008) 0.89
Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response? Expert Rev Mol Med (2008) 0.89
A clinical tool for reducing central nervous system depression among neonates exposed to codeine through breast milk. PLoS One (2013) 0.89
Current State and Future Prospects of Direct-to-Consumer Pharmacogenetics. Front Pharmacol (2012) 0.88
The pharmacokinetics of codeine and its metabolites in Blacks with sickle cell disease. Eur J Clin Pharmacol (2009) 0.88
Expression and functional analysis of CYP2D6.24, CYP2D6.26, CYP2D6.27, and CYP2D7 isozymes. Drug Metab Dispos (2008) 0.87
Introduction of the AmpliChip CYP450 Test to a South African cohort: a platform comparative prospective cohort study. BMC Med Genet (2013) 0.87
Novel drug metabolism indices for pharmacogenetic functional status based on combinatory genotyping of CYP2C9, CYP2C19 and CYP2D6 genes. Biomark Med (2011) 0.86
Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes. Pharmacogenet Genomics (2013) 0.86
CYP2D6 genotype dependent oxycodone metabolism in postoperative patients. PLoS One (2013) 0.86
Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. Eur J Clin Pharmacol (2010) 0.86
Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [13C]pantoprazole breath test. J Pharmacol Exp Ther (2009) 0.85
The Discriminatory Value of CYP2D6 Genotyping in Predicting the Dextromethorphan/Dextrorphan Phenotype in Women with Breast Cancer. Breast Care (Basel) (2012) 0.85
BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors. Eur J Clin Pharmacol (2011) 0.84
Discovery of the nonfunctional CYP2D6 31 allele in Spanish, Puerto Rican, and US Hispanic populations. Eur J Clin Pharmacol (2010) 0.84
Farnesoid X Receptor Agonist Represses Cytochrome P450 2D6 Expression by Upregulating Small Heterodimer Partner. Drug Metab Dispos (2015) 0.84
In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles. Br J Clin Pharmacol (2015) 0.84
Drug metabolizing enzyme activities versus genetic variances for drug of clinical pharmacogenomic relevance. Clin Proteomics (2011) 0.83
First demonstration that brain CYP2D-mediated opiate metabolic activation alters analgesia in vivo. Biochem Pharmacol (2013) 0.83
Uncovering drug-responsive regulatory elements. Pharmacogenomics (2015) 0.83
Pharmacogenetics of anxiolytic drugs. J Neural Transm (Vienna) (2009) 0.83
CYP2D6 and CYP2C19 in Papua New Guinea: High frequency of previously uncharacterized CYP2D6 alleles and heterozygote excess. Int J Mol Epidemiol Genet (2010) 0.82
Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial. Malar J (2016) 0.82
Association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment. J Korean Med Sci (2011) 0.82
The association of CYP2D6 genotype and postoperative nausea and vomiting in orthopedic trauma patients. Biol Res Nurs (2012) 0.81
Long-Read Single Molecule Real-Time Full Gene Sequencing of Cytochrome P450-2D6. Hum Mutat (2015) 0.81
Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol. Eur J Clin Pharmacol (2015) 0.81
Cypiripi: exact genotyping of CYP2D6 using high-throughput sequencing data. Bioinformatics (2015) 0.81
Deriving rules and assertions from pharmacogenomics knowledge resources in support of patient drug metabolism efficacy predictions. J Am Med Inform Assoc (2012) 0.81
Semi-quantitative CYP2D6 gene doses in relation to metabolic ratios of psychotropics. Eur J Clin Pharmacol (2008) 0.81
Identification of a novel non-functional CYP2D6 allele, CYP2D6*69, in a Caucasian poor metabolizer individual. Eur J Clin Pharmacol (2008) 0.81
Striking a balance in communicating pharmacogenetic test results: promoting comprehension and minimizing adverse psychological and behavioral response. Patient Educ Couns (2014) 0.80
Cytochrome P450 (CYP2D6) genotype is associated with elevated systolic blood pressure in preterm infants after discharge from the neonatal intensive care unit. J Pediatr (2011) 0.80
Influence of ABCB1 (P-glycoprotein) haplotypes on nortriptyline pharmacokinetics and nortriptyline-induced postural hypotension in healthy volunteers. Br J Clin Pharmacol (2012) 0.80
Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD. Clin Pharmacol Ther (2016) 0.79
Population prevalence of high dose paracetamol in dispensed paracetamol/opioid prescription combinations: an observational study. BMC Clin Pharmacol (2012) 0.79
CYP2D6 Haplotype Determination Using Long Range Allele-Specific Amplification: Resolution of a Complex Genotype and a Discordant Genotype Involving the CYP2D6*59 Allele. J Mol Diagn (2015) 0.79
Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population. Pharmacogenomics J (2012) 0.79
Selecting the proper pediatric dose: It is more than size that matters. Clin Pharmacol Ther (2015) 0.79
CYP2D6 genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population. Eur J Clin Pharmacol (2011) 0.79
CYP2D6 copy number distribution in the US population. Pharmacogenet Genomics (2016) 0.79
A novel simple method for determining CYP2D6 gene copy number and identifying allele(s) with duplication/multiplication. PLoS One (2015) 0.78
Nicotine Increases Codeine Analgesia Through the Induction of Brain CYP2D and Central Activation of Codeine to Morphine. Neuropsychopharmacology (2015) 0.78
Interindividual Variability in Cytochrome P450-Mediated Drug Metabolism. Drug Metab Dispos (2015) 0.78
Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjects. Br J Clin Pharmacol (2008) 0.78
Population pharmacokinetics of bisoprolol in patients with chronic heart failure. Eur J Clin Pharmacol (2012) 0.78
Reduced activities of cytochrome P450 1A2 and xanthine oxidase in children with growth hormone deficiency. Clin Pharmacol Ther (2008) 0.77
Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions. Int J Legal Med (2010) 0.77
Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics. Pharmacogenomics (2014) 0.77
High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina. Pharmacogenomics J (2016) 0.76
CYP2D6 genotyping and use of antidepressants in breast cancer patients: test development for clinical application. Metab Brain Dis (2012) 0.76
Characterization of hepatic enzyme activity in older adults with dementia: potential impact on personalizing pharmacotherapy. Clin Interv Aging (2015) 0.76
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron. Clin Pharmacol Ther (2016) 0.76
Risperidone-associated adverse drug reactions and CYP2D6 polymorphisms in a South African cohort. Appl Transl Genom (2015) 0.76
CYP2D7 Sequence Variation Interferes with TaqMan CYP2D6 (*) 15 and (*) 35 Genotyping. Front Pharmacol (2016) 0.76
Multiplex SNaPshot-a new simple and efficient CYP2D6 and ADRB1 genotyping method. Hum Genomics (2016) 0.76
Pharmacogenetic comparison of CYP2D6 predictive and measured phenotypes in a South African cohort. Pharmacogenomics J (2015) 0.76
CYP2D6 Metabolism in Frail Elderly Compared to Non-Frail Elderly: A Pilot Feasibility Study. Drugs Aging (2015) 0.75
Where Failure Is Not an Option -Personalized Medicine in Astronauts. PLoS One (2015) 0.75
Tailoring adjuvant endocrine therapy for postmenopausal breast cancer: a CYP2D6 multiple-genotype-based modeling analysis and validation. PLoS One (2010) 0.75
Flexible and Scalable Full-Length CYP2D6 Long Amplicon PacBio Sequencing. Hum Mutat (2017) 0.75
Use of sodium taurocholate to enhance spore recovery on a medium selective for Clostridium difficile. J Clin Microbiol (1982) 4.35
Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature (1996) 4.04
Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther (2008) 2.31
Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin Pharmacol Ther (2007) 2.17
Ecology of Candida albicans gut colonization: inhibition of Candida adhesion, colonization, and dissemination from the gastrointestinal tract by bacterial antagonism. Infect Immun (1985) 2.03
Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Pharmacokinet (1999) 1.79
High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol (1997) 1.75
Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet (1999) 1.67
High incidence of focal segmental glomerulosclerosis in nephrotic syndrome of childhood. Pediatr Nephrol (1999) 1.62
Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. JAMA (1999) 1.49
Effect of various antibiotics on gastrointestinal colonization and dissemination by Candida albicans. Sabouraudia (1985) 1.43
High-dose chemotherapy of breast cancer: is the question answered? J Clin Oncol (1995) 1.43
Inactivation of Serpulina hyodysenteriae flaA1 and flaB1 periplasmic flagellar genes by electroporation-mediated allelic exchange. J Bacteriol (1995) 1.42
Identification of Pasteurella multocida virulence genes in a septicemic mouse model using signature-tagged mutagenesis. Microb Pathog (2000) 1.42
Semen quality and hormone levels among radiofrequency heater operators. J Occup Environ Med (2000) 1.41
Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics (1999) 1.36
Acetaminophen overdose with therapeutic intent. J Pediatr (1998) 1.29
Adhesion and association mechanisms of Candida albicans. Curr Top Med Mycol (1988) 1.24
Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. Clin Pharmacol Ther (2008) 1.22
Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione. Implications for idiosyncratic toxicity. Drug Metab Dispos (1992) 1.17
Metabolic syndrome, central obesity and insulin resistance are associated with adverse pathological features in postmenopausal breast cancer. Clin Oncol (R Coll Radiol) (2010) 1.17
Fatigue, pain, and depression in pre-autotransplant breast cancer patients. Cancer Pract (2000) 1.16
Dual flaA1 flaB1 mutant of Serpulina hyodysenteriae expressing periplasmic flagella is severely attenuated in a murine model of swine dysentery. Infect Immun (1996) 1.16
Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy. Eur J Surg Oncol (2005) 1.13
Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail". Clin Pharmacol Ther (2000) 1.12
The effectiveness of the comprehensive coping strategy program on clinical outcomes in breast cancer autologous bone marrow transplantation. Cancer Nurs (2000) 1.11
Progressive ratio and fixed ratio schedules of cocaine-maintained responding in baboons. Psychopharmacology (Berl) (1979) 1.05
Use of a microplate reader in an assay of glutathione reductase using 5,5'-dithiobis(2-nitrobenzoic acid). Anal Biochem (1989) 1.05
Factors influencing infant visits to emergency departments. Pediatrics (2000) 1.04
Identification of Actinobacillus pleuropneumoniae virulence genes using signature-tagged mutagenesis in a swine infection model. Microb Pathog (2000) 1.04
Bendectin: the wrong way to regulate drug availability. Can Med Assoc J (1983) 1.04
Ceftazidime disposition in acute and stable cystic fibrosis. Clin Pharmacol Ther (1984) 1.03
NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations. Pharmacogenetics (1998) 1.03
Evaluation of ivermectin on performance of beef cattle on pasture in alberta. Can Vet J (1988) 1.02
Persistent infection with neurotropic herpes viruses and cognitive impairment. Psychol Med (2012) 1.01
Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine. Drug Metab Dispos (1999) 0.99
Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping. Clin Pharmacol Ther (1998) 0.99
Measuring male reproductive hormones for occupational field studies. J Occup Med (1993) 0.99
Multiple lymphomatous polyposis of the gastrointestinal tract. A clinicopathologically distinctive form of non-Hodgkin's lymphoma of B-cell centrocytic type. Am J Surg Pathol (1989) 0.99
Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans. Pharmacogenomics J (2005) 0.99
trans-6-Hexadecenoic acid in the spadefish Chaetodipterus faber. Lipids (1976) 0.98
Angiostrongylosis with disseminated larval infection associated with signs of ocular and nervous disease in an imported dog. Can Vet J (1991) 0.98
HIV gp120- and methamphetamine-mediated oxidative stress induces astrocyte apoptosis via cytochrome P450 2E1. Cell Death Dis (2013) 0.96
Longitudinal study of semen quality of unexposed workers. I. Study overview. Reprod Toxicol (1988) 0.95
Staphylococcal exotoxins stimulate nitric oxide-dependent murine macrophage tumoricidal activity. Infect Immun (1991) 0.95
Feasibility and efficacy of a supervised exercise intervention in de-conditioned cancer survivors during the early survivorship phase: the PEACH trial. J Cancer Surviv (2013) 0.94
High-pressure liquid chromatographic analysis of ceftazidime in serum and urine. Antimicrob Agents Chemother (1983) 0.94
Acetaminophen intoxication during treatment: what you don't know can hurt you. Clin Pediatr (Phila) (2000) 0.94
Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. Can J Physiol Pharmacol (2001) 0.94
Investigation of terbinafine as a CYP2D6 inhibitor in vivo. Clin Pharmacol Ther (1999) 0.93
Lung particulate burdens of subjects from the Cincinnati, Ohio urban area. Scanning Microsc (1991) 0.93
A method for meta-analysis of epidemiological studies. Drug Intell Clin Pharm (1988) 0.93
Detection of tumor cells in the bone marrow, peripheral blood, and apheresis products of breast cancer patients using flow cytometry. Exp Hematol (1995) 0.93
Restriction of antigen recognition in mouse B lymphocytes by genes mapping within the major histocompatibility complex. J Immunol (1980) 0.92
Post-traumatic degenerative arthrosis in the manubriosternal joint. Clin Orthop Relat Res (1970) 0.91
Dissemination of yeasts after gastrointestinal inoculation in antibiotic-treated mice. Sabouraudia (1983) 0.91
Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Drug Metab Dispos (1997) 0.91
Cyclophosphamide and 4-Hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy. Clin Cancer Res (1996) 0.91
Spontaneous regression of metastatic Merkel cell carcinoma. Ir Med J (2010) 0.91
Impact of age on outcome of patients with cancer undergoing autologous bone marrow transplant. J Clin Oncol (1996) 0.90
Regulation of Candida albicans populations in the gastrointestinal tract: mechanisms and significance in GI and systemic candidiasis. Curr Top Med Mycol (1989) 0.90
Creatinine excretion rates for renal clearance studies. Pediatr Nephrol (2001) 0.90
Specificity of effector T lymphocytes in autologous graft-versus-host disease: role of the major histocompatibility complex class II invariant chain peptide. Blood (1997) 0.89
Fenoprofen and agranulocytosis. N Engl J Med (1978) 0.89
Isolation, oxygen sensitivity, and virulence of NADH oxidase mutants of the anaerobic spirochete Brachyspira (Serpulina) hyodysenteriae, etiologic agent of swine dysentery. Appl Environ Microbiol (1999) 0.89
High frequency of CYP2D6 poor and "intermediate" metabolizers in black populations: a review and preliminary data. Psychopharmacol Bull (1998) 0.89
A rapidly acquired one-way conditioned avoidance procedure in rats as a primary screening test for antipsychotics: influence of shock intensity on avoidance performance. Behav Brain Res (1988) 0.88
Intake and blood levels of fatty acids in treated patients with phenylketonuria. J Pediatr Gastroenterol Nutr (2001) 0.88
A tethering system for intravenous and intragastric drug administration in the baboon. Pharmacol Biochem Behav (1982) 0.88
The excessive cost of baseline diagnostic imaging in early breast cancer. Ir Med J (2009) 0.88
Testing the 'teachable moment' premise: does physical activity increase in the early survivorship phase? Support Care Cancer (2013) 0.88
Activities of an employer independent Occupational Medicine Clinic, Cook County Hospital, 1979-1981. Am J Public Health (1982) 0.88
Effect of ivermectin on weight gains on yearling steers on pasture in central Alberta. Can Vet J (1989) 0.88
Biochemical analysis of phototransduction and visual cycle in zebrafish larvae. Methods Enzymol (2000) 0.87
Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping. Pharmacogenetics (1998) 0.87
Exogenous C1q reconstitutes resident but not inflammatory mouse peritoneal macrophages for Fc receptor-dependent cellular cytotoxicity and phagocytosis. Relationship to endogenous C1q availability. J Immunol (1989) 0.87
Inhibition of Candida albicans by the anaerobic oral flora of mice in vitro. Sabouraudia (1981) 0.87
Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype. J Chromatogr B Biomed Sci Appl (1998) 0.87
Activity of fulvestrant in HER2-overexpressing advanced breast cancer. Ann Oncol (2009) 0.87
Normal urinary calcium/creatinine ratios in African-American and Caucasian children. Pediatr Nephrol (2001) 0.86
Linkage analysis of schizophrenia in African-American families. Schizophr Res (2009) 0.86
Benzimidazole resistance in horses in western Canada. Can Vet J (1989) 0.86
First report of Ollulanus tricuspis (Nematoda) from western Canada. J Parasitol (1984) 0.86
Recent advances in systemic therapy for breast cancer. Curr Opin Oncol (1998) 0.85
Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer. Ann Oncol (2013) 0.85
The effect of aerobic exercise on metabolic and inflammatory markers in breast cancer survivors--a pilot study. Support Care Cancer (2013) 0.85
Effects of valproic acid on organic acid metabolism in children: a metabolic profiling study. Clin Pharmacol Ther (2011) 0.85
An outbreak of multiply resistant Serratia marcescens: the importance of persistent carriage. Bone Marrow Transplant (2000) 0.85
Galactose breath testing distinguishes variant and severe galactose-1-phosphate uridyltransferase genotypes. Pediatr Res (2000) 0.84
Transitioning preterm infants with nasogastric tube supplementation: increased likelihood of breastfeeding. J Obstet Gynecol Neonatal Nurs (1999) 0.84
Glucagon therapy for beta-blocker overdose. Drug Intell Clin Pharm (1984) 0.84
Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Cancer Res (1995) 0.83
Longitudinal study of semen quality of unexposed workers: sperm head morphometry. J Androl (1990) 0.83
Unique Immunogenic Proteins in Heterodera glycines Eggshells. J Nematol (1997) 0.83
In vitro analysis of metabolic predisposition to drug hypersensitivity reactions. Clin Exp Immunol (1995) 0.83